Wei Zhang, Ph.D.
As an advisor to Red Sky Partners, Wei works with biotech clients in the US and China on corporate strategy including early stage financing and business development. He has over 20 years of experience as a biotech operating experience and as an investor in biotech companies. He has an extensive network in both the US and Chinese biotech industries.
Previously, Wei was President and CEO of an early stage biotech focusing on novel predictive models for cancer and autoimmune drug development. He also led corporate development at Good Start Genetics, a commercial stage genetic testing company which he invested on as a venture capitalist at Safeguard Scientifics, an NYSE listed investment firm with 60 years of history. At Safeguard, Wei was a key member of the healthcare team that was responsible for exits through 8 M&A and IPO that were valued more than $2B. Wei had also worked part-time and consulted for several funds in the US and China when he was at Wharton.
Wei started his career as a scientist and manager with increased responsibilities at both innovative biotech and large pharm companies. He started his scientific career at Lilly’s Sphinx division, and then at Genetics Institute (now Pfizer) and ImmunoGen. Wei had worked on development of more than 20 biological drugs for cancer, autoimmune and CNS diseases, including several currently on the market. Wei is an inventor of over a dozen issued and pending patents and author of 17 scientific publications.
Wei is also a Kauffman Fellow, a global program with 500 investors and innovators.
Wei received BS in chemistry from Nanjing University in China, PhD in chemistry from Boston University. He also obtained MBA in healthcare and finance from Wharton and was awarded Wharton Healthcare Entrepreneurship Scholarship.